Skip to ContentSkip to Navigation
How to find us prof. dr. E.M.D. (Ed) Schuuring


A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses

Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature

Biomarker testing in oncology - Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm

Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients

DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population

Evaluation of Combined Biomarker of Response to Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer

First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers

High DNMT1 Is Associated With Worse Local Control in Early-Stage Laryngeal Squamous Cell Carcinoma

Read more


At ESMO, Focusing on Non-Small Cell Lung Cancer


“Betere diagnostiek verhoogt overlevingskans”

“Celvrij DNA-onderzoek nog niet klaar voor kliniek”

diagnostisch onderzoek naar longkanker kan nieuwe/betere behandelmethode bieden

Gezamenlijke visie Groningen op biomarkers, bioanalyse en diagnostiek heeft nationaal zijn weerga

UMCG ontvangt 4 ton subsidie voor onderzoek baarmoederhalskanker

UMCG krijgt vier ton subsidie voor verbetering onderzoek naar baarmoederhalskanker.

Read more